CALL/AMGEN/350/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 15:26:01 19/06/2024 BST | ||
| 0.004 EUR | -20.00% |
|
| Current month | -78.95% | ||
| 1 month | -93.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 0.004 | -20.00% |
| 18/06/24 | 0.005 | -16.67% |
| 17/06/24 | 0.006 | -14.29% |
| 14/06/24 | 0.007 | -36.36% |
| 13/06/24 | 0.011 | +10.00% |
Real-time BOERSE MUENCHEN
Last update June 19, 2024 at 03:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GZ901F |
| ISIN | DE000GZ901F2 |
| Date issued | 20/02/2023 |
| Strike | 350 $ |
| Maturity | 21/06/2024 (2 Days) |
| Parity | 10 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.94 € |
|---|---|
| Lowest since issue | 0.004 € |
| Spread | 0.07 € |
| Spread % | 95.89% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
306
USD
Average target price
316.4
USD
Spread / Average Target
+3.42%
- Stock Market
- Warrants
- Warrant
